Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 11.9% from a year ago
Common stock stood at $245K at the end of Q1 FY2026, up 11.9% from a year earlier and up 7.0% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +11.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 229K USD
- Year-over-year change
- +8.0%
- 4-year CAGR
- +12.7%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 229K | +8.0% |
| FY2024 | 2024-12-31 | 212K | +25.4% |
| FY2023 | 2023-12-31 | 169K | +17.4% |
| FY2022 | 2022-12-31 | 144K | +1.4% |
| FY2021 | 2021-12-31 | 142K | — |
Common Stock vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's Mar 2026 common stock of $245K is the 2nd highest of the 9 companies compared; the peer median is $11K.
- Its year-over-year change of +11.9% is the 3rd highest of 9, against a peer median of +0.6%.
- Common stock amounts to 0.1% of total assets for ALLO, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.92M | +0.3% | +25.9% | 2.0% | |
| Mar 2026 | $245K | +11.9% | +16.7% | 0.1% | |
| Mar 2026 | $116K | +0.9% | +5.8% | 0.0% | |
| Mar 2026 | $18K | +100.0% | +14.5% | 0.0% | |
| Mar 2026 | $12K | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $10K | +11.1% | +14.5% | 0.0% | |
| Dec 2025 | $3K | +50.0% | -41.5% | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $1K | +0.0% | -53.6% | 0.0% | |
| Peer median (excluding ALLO) | $11K | +0.6% | +10.2% | 0.0% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 173.31M | 61.9M | 83.16M | 75.22M | 51.69M |
| Short-term Investments | 283.99M | 455.42M | 365.54M | 217.26M | 198.52M |
| Net Receivables | 0 | 0 | 1.7M | 1.9M | 1.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 11.5M | 0 | 9.01M | 6.04M |
| Total Current Assets | 471.32M | 528.82M | 459.12M | 303.39M | 257.75M |
| Property, Plant & Equipment (Net) | 181.02M | 196.43M | 163.18M | 131.26M | 112.73M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 382.38M | 76.47M | 3.65M | 80.67M | 8.04M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 16.11M | 19.86M | 16.9M | 33.39M | 37.39M |
| Total Non-current Assets | 579.51M | 292.76M | 183.72M | 245.32M | 158.16M |
| Total Assets | 1.05B | 821.58M | 642.84M | 548.71M | 415.91M |
| Account Payables | 10.26M | 13.89M | 5.9M | 5.39M | 4.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 156K | 95K | 86K | 0 | 0 |
| Other Current Liabilities | 16.13M | 17.94M | 11.66M | 12.15M | 10.24M |
| Total Current Liabilities | 47.91M | 53.73M | 37.08M | 35.52M | 32.51M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.79M | 5.85M | 5.18M | 7.76M | 15.8M |
| Total Non-current Liabilities | 77.72M | 100.97M | 93.53M | 91.01M | 90.85M |
| Total Liabilities | 125.63M | 154.7M | 130.6M | 126.53M | 123.36M |
| Common Stock | 142K | 144K | 169K | 212K | 229K |
| Retained Earnings | (894.55M) | (1.23B) | (1.56B) | (1.82B) | (2.01B) |
| Accumulated OCI | (2.57M) | (9.93M) | (955K) | (89K) | 269K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 925.2M | 666.88M | 512.23M | 422.18M | 292.54M |
| Total Debt | 73.13M | 101.12M | 95.12M | 90.76M | 83.25M |
| Net Debt | (100.19M) | 39.22M | 11.97M | 15.54M | 31.57M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.